A Phase 3 interventional study of GB-0998 (Intravenous immunoglobulin) and Plasmapheresis in Generalized Myasthenia Gravis, sponsored by Benesis Corporation. Completed at 1 site in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2010-07-30.
Sponsored by Benesis Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Myasthenia Gravis with a site in Japan — 10 open to participants now, 20 under way, 15 of them phase 3. Myasthenia Gravis · Japan.
Among the 42 studies in Myasthenia Gravis with a site in Japan, this one is the 31st largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2007, is one of 35 in phase 3, and was the 4th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →10 of the 42 studies in Myasthenia Gravis with a site in Japan are open now. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in Japan, United States, China and 4 more countries
Ages 18+
argenx · Sites in Japan, United States, Belgium and 4 more countries
Ages 18+
UCB Biopharma SRL · Sites in Japan, United States, Canada and 6 more countries
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in Japan, United States, Germany and 1 more country
Ages 18+
argenx · Sites in Japan, United States, Belgium and 5 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 37 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is close to the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 125 across the 41 interventional studies, 70 across the 1 observational. Of the 22 that completed or were terminated, 16 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 42 have an industry lead sponsor. The 10 most frequent:
Benesis Corporation is the lead sponsor of 2 studies on the registry; none are open to participants now.
Benesis Corporation has 1 study filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
7 of the studies in Myasthenia Gravis with a site in Japan that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
| NCT05265273Phase 3Janssen Research & Development, LLCA Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | 2027-06-30 |
| NCT06540144Phase 3UCB Biopharma SRLAn Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | 2027-10-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 42 studies in Myasthenia Gravis with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled, multi-center study will carry out to assess the efficacy of GB-0998 compared to plasmapheresis in the treatment of the generalized Myasthenia Gravis based on the changes in Quantitative Myasthenia Gravis score (QMG score) as primary endpoint, and in addition, to assess the safety of GB-0998
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: GB-0998 (Intravenous immunoglobulin)
Procedure: Plasmapheresis
Also known as: Venoglobulin-IH
Changes in QMG score
Time frame: at 4 weeks
Changes of QMG score, MG-ADL scale, anti-acetylcholine receptor antibody levels
Time frame: from beginning of the treatment through 4th week
The record gives a start of Jul 2007, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Benesis Corporation